Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

Publication date: Available online 16 March 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Erden Atilla, Ugur Sahin, Pinar Ataca Atilla, Mustafa Merter, Elif Ozyurek, Koray Ceyhan, Sinem Civriz BozdagAbstractPrimary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether graft versus lymphoma effect can work in PCNSL patients. Here, we present a relapsed refractory PCNSL case treated by allo-HCT.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research